ARA-290 vs VIP
Both ARA-290 and VIP are used for anti-inflammatory and neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.
ARA-290
Evidence BARA-290 (Cibinetide)
An 11-amino-acid peptide derived from the helix-B region of erythropoietin. Activates the tissue-protective receptor without erythropoietic side effects. Investigated for neuropathy and inflammation.
View full ARA-290 profile →VIP
Evidence BVasoactive Intestinal Peptide
A 28-amino-acid neuropeptide with broad immunomodulatory effects. Used clinically (intranasal) by some practitioners for chronic inflammatory response syndrome (CIRS).
View full VIP profile →Side-by-Side
| Attribute | ARA-290 | VIP |
|---|---|---|
| Evidence Grade | B | B |
| FDA Status | Not FDA-approved — Phase 2/3 trials for sarcoidosis-associated small fiber neuropathy | Not FDA-approved — investigational; ongoing trials for sarcoidosis |
| Typical Dose | Trial range: 1–4 mg subcutaneous daily | 50 mcg intranasal, 4 times daily (CIRS protocols) |
| Clinics Indexed | 9 | 24 |
| Categories | anti-inflammatory, neuroprotection | anti-inflammatory, neuroprotection |
Key reported benefits — ARA-290
- ✓Small-fiber neuropathy improvement
- ✓Anti-inflammatory
- ✓No erythrocytosis
Key reported benefits — VIP
- ✓Anti-inflammation
- ✓Pulmonary effects
- ✓Neuroprotection
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.